List of Excipients in Branded Drug HEMANGEOL

« Back to Dashboard

Hemangeol Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Hemangeol is a propranolol hydrochloride oral solution for treating proliferating infantile hemangioma requiring systemic therapy. Its commercial value is concentrated in pediatric usability: accurate low-volume dosing, acceptable taste, oral-solution stability, and caregiver safety. The core formulation uses a sugar-free aqueous vehicle with hydroxyethylcellulose, citrate buffering, saccharin sodium, strawberry flavor, propylene glycol, and purified water. The strongest commercial opportunities are improved palatability, preservative-free stability, dosing-device integration, age-specific presentations, and differentiated formulations that reduce dosing errors.

What is Hemangeol and what excipients does it contain?

Hemangeol is an oral solution containing propranolol hydrochloride equivalent to 3.75 mg/mL of propranolol base. The labeled concentration of propranolol hydrochloride is 4.28 mg/mL. It is administered orally to pediatric patients with proliferating infantile hemangioma.

The U.S. product is supplied as a ready-to-use oral solution rather than a powder for reconstitution or a compounded preparation. The FDA labeling identifies the following inactive ingredients:

Excipient	Primary formulation role
Purified water	Aqueous vehicle
Hydroxyethylcellulose	Viscosity control and suspension uniformity
Citric acid monohydrate	Acidification and buffering
Sodium citrate dihydrate	Buffering and pH control
Saccharin sodium	Sweetener and taste masking
Strawberry flavor	Palatability
Propylene glycol	Solvent and flavor carrier

The commercial formulation is sugar-free. That is relevant in infants because repeated dosing can increase exposure to fermentable carbohydrates and may complicate dental and metabolic positioning. The absence of sucrose also supports use in children who require prolonged treatment, although the product still requires administration with feeding to reduce hypoglycemia risk. [1]

The public label does not disclose the quantitative concentration of every excipient. This limits direct assessment of preservative burden, propylene glycol exposure, buffer capacity, and flavor-loading strategy from the label alone.

How does the Hemangeol formulation support pediatric use?

The formulation is designed around four clinical and commercial requirements:

1. Low-volume dosing. The 3.75 mg/mL propranolol concentration permits weight-based administration without the high volumes associated with dilute compounded liquids.
2. Taste masking. Strawberry flavor and saccharin sodium address the bitter taste of propranolol.
3. Dose uniformity. Hydroxyethylcellulose increases viscosity and can help maintain a homogeneous solution during handling and dosing.
4. pH control. The citric acid and sodium citrate system supports chemical stability and palatability.

Hemangeol dosing is weight-based and must be adjusted as the child gains weight. A calibrated oral syringe is therefore commercially important. The dosing system is part of the product's practical value even though it is not an active pharmaceutical ingredient.

The label instructs caregivers to administer the product during or immediately after feeding and to withhold doses when the child is fasting or vomiting. This makes administration instructions, syringe design, and caregiver education important components of the product's risk-management strategy. [1]

What excipient strategies could improve Hemangeol or competing propranolol solutions?

Improve taste without increasing pediatric excipient burden

Propranolol has a strong bitter taste. Commercially useful approaches include:

• Multi-flavor screening using strawberry, berry, vanilla, or fruit blends.
• Taste-masking systems based on ion pairing, cyclodextrins, or polymeric complexes.
• Reduced saccharin reliance through high-intensity sweetener combinations.
• Flavor systems with lower propylene glycol content.
• Flavor persistence testing after administration with food or milk.

A reformulation must preserve chemical stability, dose uniformity, and acceptability across infants, toddlers, and caregivers. A flavor change alone may not create defensible intellectual property, but a defined taste-masking system combined with stability and low-dose performance could support a formulation patent.

Develop preservative-free stability

A preservative-free product has commercial appeal in infants, particularly where the product is used for months. The main technical challenge is microbial control after opening.

Potential approaches include:

• Optimized container-closure systems.
• Unit-dose ampoules or sachets.
• Blow-fill-seal packaging.
• Metered oral dispensers.
• Lower microbial-risk formulation design.
• In-use stability supported by validated handling instructions.

A preservative-free formulation with a documented in-use period could compete against products that rely on conventional multidose packaging. The value depends on manufacturing cost, package complexity, and whether the product requires refrigeration or special handling.

Reduce or replace propylene glycol

Propylene glycol is used widely as a solvent and flavor carrier, but its presence creates a pediatric-excipient review issue. Exposure is generally dose-dependent and must be assessed against age, weight, duration, and total medication burden. Alternative solvent systems could include glycerol, polyethylene glycol grades with appropriate pediatric acceptability, or flavor systems that require less carrier solvent.

A commercially meaningful reformulation would need to demonstrate:

• Lower daily excipient exposure.
• Equivalent propranolol solubility.
• Equivalent or improved taste.
• No increase in degradation products.
• No loss of microbiological quality.
• Acceptable viscosity and syringe performance.

A lower-propylene-glycol formulation could support premium positioning, particularly in neonatal and younger-infant segments. It would also create a potential line-extension strategy if the product could be supported without changing the clinically familiar propranolol concentration.

Improve dosing accuracy

Dosing error is a material risk in weight-based pediatric therapy. Commercial opportunities include:

• Oral syringes with dose markings aligned to the product concentration.
• Low-dead-space syringes.
• Child-specific dosing aids.
• QR-linked weight-based dosing tools.
• Packaging that separates the bottle from the syringe only when needed.
• Unit-dose packs for hospital discharge.

The strongest differentiation would combine the formulation with a validated delivery device. A device-enabled product may obtain separate patent protection, although device and combination-product regulatory analysis would be required.

What formulations are protected by Hemangeol-related intellectual property?

The likely protection categories for Hemangeol and competing propranolol products include:

Protection category	Potential subject matter	Commercial relevance
Active ingredient use	Propranolol for infantile hemangioma	May support method-of-use claims
Oral solution	Specific concentration and liquid dosage form	Can limit direct formulation copying
Excipients	Buffer, thickener, sweetener, flavor, solvent combinations	Relevant to differentiated generics and line extensions
Stability	pH range, degradation control, shelf life, in-use stability	Raises manufacturing and regulatory barriers
Packaging	Bottles, syringes, unit-dose systems, closure designs	Supports product-device differentiation
Dosing method	Weight-based administration and feeding-related instructions	May overlap with labeling and method-of-use claims

A proprietary excipient combination is most defensible when the applicant can show an unexpected result, such as improved stability, lower bitterness, reduced precipitation, lower impurity formation, or superior dose recovery from the container.

The U.S. Orange Book may list patents associated with an approved drug product, but Orange Book status must be evaluated by product, patent number, claim scope, and current listing status. A formulation patent may have limited practical value if a competitor can design around the excipient combination while maintaining the same propranolol concentration and indication.

When does Hemangeol lose exclusivity?

Hemangeol received FDA approval on March 14, 2014, under NDA 205410. It received orphan-drug designation for infantile hemangioma. The standard orphan-drug exclusivity period is seven years from approval, placing the expected orphan exclusivity endpoint in March 2021. [1,2]

Orphan exclusivity is separate from patent protection. It prevents FDA approval of the same drug for the same orphan indication during the exclusivity period, subject to statutory exceptions. It does not prevent all propranolol products from entering other markets or being used under other legal pathways.

Hemangeol is a small-molecule drug, so biosimilar exclusivity does not apply. Competitive pressure comes from generic propranolol products, compounded solutions, off-label dosage forms, and alternative infantile hemangioma treatments.

What is the FDA and Orange Book status of Hemangeol?

Hemangeol is FDA-approved as an oral solution for pediatric patients with proliferating infantile hemangioma requiring systemic therapy. Its regulatory differentiation comes from the approved indication, concentration, dosing instructions, manufacturing controls, and labeled safety information.

The relevant regulatory considerations for a competing product include:

• Whether the product is an approved generic under an abbreviated new drug application.
• Whether the applicant matches the reference concentration and dosage form.
• Whether the product carries the same indication or relies on another legal basis.
• Whether listed patents create Paragraph IV certification risk.
• Whether the applicant must address formulation, labeling, or device differences.
• Whether the product is a compounded preparation outside the approved-drug pathway.

A generic propranolol oral solution could compete on price without reproducing every Hemangeol excipient. It may use a different flavor, sweetener, viscosity modifier, or preservative system if the product meets applicable quality, equivalence, and labeling requirements.

What Paragraph IV and generic-entry risks affect Hemangeol?

The main generic-entry risks are formulation design-around, indication strategy, and compounded-product substitution.

Formulation design-around

A challenger may reproduce the clinical concentration while changing:

• Flavor.
• Sweetener.
• Buffer system.
• Thickener.
• Solvent.
• Container closure.
• Oral syringe configuration.

This can reduce exposure to composition claims while preserving the core commercial attributes of the reference product.

Paragraph IV risk

If an unexpired patent is listed in the Orange Book, an ANDA applicant may certify that the patent is invalid, unenforceable, or will not be infringed. A Paragraph IV notice can lead to patent litigation and a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory exceptions and procedural developments. [3]

The commercial value of a listed formulation patent depends on claim breadth. Claims limited to a particular flavor or excipient concentration are easier to design around than claims covering a broad, unexpected stability or taste-masking system.

Compounded-product substitution

Compounded propranolol liquids may compete with branded and generic products, especially when pharmacy access, payer coverage, or local prescribing habits favor compounding. Approved commercial products retain advantages in validated stability, standardized concentration, labeling, and manufacturing oversight.

How does Hemangeol compare with alternative infantile hemangioma treatments?

Treatment	Dosage form	Main commercial advantage	Excipient opportunity
Hemangeol	Propranolol oral solution	Approved systemic therapy with pediatric concentration	Taste, dosing, packaging, stability
Compounded propranolol	Pharmacy-prepared liquid	Local availability and potential lower cost	Standardization and preservative reduction
Oral propranolol tablets	Solid dosage form	Lower manufacturing complexity	Pediatric dispersion and dose flexibility
Topical timolol	Gel or solution	Useful for selected superficial lesions	Skin tolerability and delivery
Atenolol	Oral systemic therapy in selected practice settings	May avoid some propranolol-specific concerns	Pediatric liquid design and evidence generation

Hemangeol's main competitive advantage is a product-specific pediatric liquid presentation supported by clinical and regulatory data. A generic can erode price while still leaving opportunities for premium products with better taste, packaging, and caregiver usability.

What commercial opportunities exist for Hemangeol excipients?

Premium pediatric formulation

A reformulated product could target:

• Lower propylene glycol exposure.
• No artificial sweetener.
• Improved bitterness reduction.
• Longer in-use stability.
• Preservative-free packaging.
• More accurate low-volume dosing.

Hospital and discharge packaging

Unit-dose or starter packs could improve discharge logistics and reduce first-dose errors. A hospital-focused package could include a calibrated syringe, treatment initiation instructions, and a weight-adjustment chart.

Geographic expansion

Excipient preferences and regulatory requirements vary by market. Opportunities include:

• Ethanol-free formulations where pediatric solvent restrictions are more stringent.
• Lower-allergen flavor systems.
• Halal- or vegetarian-compatible excipients.
• Region-specific sweetener and flavor systems.
• Packaging adapted to local dosing practices.

A global formulation should avoid unnecessary differences in concentration because concentration changes create medication-error risk and complicate prescriber conversion.

Licensing and partnering

Potential licensing assets include:

• Pediatric taste-masking technology.
• Low-solvent oral liquid platforms.
• Preservative-free multidose packaging.
• Oral syringe and bottle systems.
• Propranolol stability technology.
• Ready-to-use liquid manufacturing capacity.

The most attractive licensing package would combine a formulation platform with clinical acceptability data and a manufacturing process that can scale without costly aseptic operations.

How strong is the Hemangeol formulation patent estate?

The commercial strength of the estate depends on three factors:

1. Claim coverage. Broad claims covering the concentration, dosage form, and functional excipient combination are stronger than narrow flavor-specific claims.
2. Design-around difficulty. A competitor can avoid narrow claims by changing flavor, buffer, or thickener.
3. Regulatory dependence. If the product's clinical and commercial performance depends on a precise excipient system, design-around may require new stability and palatability studies.

Method-of-use protection may have more value than a narrow excipient claim where the product is tied to a defined infantile hemangioma dosing regimen. The absence of biosimilar risk does not eliminate generic risk because propranolol is a well-established small molecule with multiple possible liquid formulations.

Key Takeaways

• Hemangeol is a 3.75 mg/mL propranolol oral solution for infantile hemangioma.
• Its labeled excipients include hydroxyethylcellulose, citrate buffer components, saccharin sodium, strawberry flavor, propylene glycol, and purified water.
• The principal commercial advantages are pediatric concentration, ready-to-use dosing, sugar-free formulation, and approved labeling.
• The strongest excipient opportunities are taste masking, reduced propylene glycol, preservative-free stability, and integrated dosing systems.
• Orphan-drug exclusivity from the 2014 approval likely ended in March 2021; patent protection must be assessed separately.
• Generic and compounded propranolol products create greater risk than biosimilars, which are not relevant to this small-molecule product.
• Formulation patents are most valuable when they cover a broad, difficult-to-design-around system supported by unexpected stability or palatability results.

FAQs

Can Hemangeol excipients be changed without a new FDA approval?

No. A material excipient change generally requires regulatory assessment because it can affect stability, bioavailability, microbiological quality, tolerability, and labeling.

Is Hemangeol sugar-free?

Yes. The labeled formulation does not list sucrose or another conventional sugar as an inactive ingredient. [1]

Does Hemangeol contain propylene glycol?

Yes. Propylene glycol is listed among the inactive ingredients in the U.S. prescribing information. [1]

Can a generic propranolol solution use different flavors or sweeteners?

Potentially. A generic may use different inactive ingredients if it satisfies applicable FDA requirements and does not infringe relevant patents or exclusivity rights.

Is a compounded propranolol solution equivalent to Hemangeol?

Not automatically. Compounded products can differ in concentration, excipient composition, stability, dosing accuracy, quality controls, and labeling. Clinical substitution should not be treated as an assumption of pharmaceutical equivalence.

References

1. U.S. Food and Drug Administration. (2023). Hemangeol (propranolol hydrochloride) oral solution: Prescribing information. Pierre Fabre Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/orphan-drug-designation-and-exclusivity

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files